Clinical2023
In a phase 2 randomized trial, oral orforglipron produced up to ~14.7% mean weight loss at 36 weeks in adults with obesity or overweight.
Significant weight loss (up to 12.4% at 72 weeks)
anecdotal
0 views
Orforglipron
Orforglipron (LY-3502970) is an oral, non-peptide GLP-1 receptor agonist - the first small-molecule GLP-1 to complete Phase 3 trials.
Overview
Orforglipron (LY-3502970) is an oral, non-peptide GLP-1 receptor agonist - the first small-molecule GLP-1 to complete Phase 3 trials. Unlike injectable GLP-1s, it requires no injections, refrigeration, or food/water restrictions. Clinical trials show substantial weight loss (up to 12.4% at 72 weeks) and robust glycemic control (HbA1c reductions of 1.3-1.6%). Developed by Chugai Pharmaceutical and licensed to Eli Lilly, FDA approval expected 2026.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
OrforglipronLY-3502970Oral nonpeptide GLP-1 receptor agonist
Status: Investigational - not yet FDA-approved; FDA approval expected 2026
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Obesity / weight managementType 2 diabetesOral GLP-1 receptor agonists
Available Evidence
Human
Phase 2 trials: once-daily oral orforglipron produced dose-dependent weight loss — up to ~14.7% mean reduction at 36 weeks in adults with obesity (NEJM 2023) — and substantial HbA1c reductions in type 2 diabetes (Lancet 2023). Phase 3 ATTAIN-1 (2025) reported sustained weight loss (~12.4% average at 72 weeks), and an NDA has been submitted to the FDA.
Animal
Preclinical studies in rodent models of obesity/diabetes confirmed weight loss and glycemic effects with the small-molecule GLP-1 agonist.
In Vitro
Orforglipron is a potent full agonist of the human GLP-1 receptor in cell-based assays, comparable to peptide GLP-1 receptor agonists.
Uncertain
Gastrointestinal side effects (nausea, vomiting, diarrhea) are common; ALT elevations were observed in some trials and long-term cardiovascular and liver safety are still being characterized.
Key Studies & Findings
Clinical2023
A phase 2 dose-response study in type 2 diabetes showed HbA1c reductions up to ~2.1% at 26 weeks with once-daily orforglipron.
Clinical2025
Phase 3 ATTAIN-1 results showed sustained weight loss (average ~12.4% at 72 weeks; up to ~27.3 lb in a first pivotal trial), supporting an FDA NDA submission.
Benefits & Effects
robust diabetes control (HbA1c reduction 1.3-1.6%)
anecdotal
once-daily oral tablet
anecdotal
no refrigeration or food restrictions
anecdotal
reduced cardiovascular risk markers
anecdotal
preserved muscle mass during weight loss
anecdotal
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
Orforglipron is investigational and not yet FDA-approved at review date. Long-term safety (GI tolerability, liver-enzyme signals, cardiovascular outcomes) is still being assessed, and full phase 3 publications are pending peer review.
Pharmacology
Once-daily oral small-molecule full agonist of the GLP-1 receptor (no peptide, no refrigeration, no food/water restrictions per phase 1 data); trial doses ranged roughly from 1–45 mg once daily. Gastrointestinal tolerability is the main dose-limiting factor.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
3mg daily
Route: Oral
Half-life: 1.2 days – 2.0 days
Research Protocols
Type 2 diabetes initiation
- Dose
- 3mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Type 2 diabetes moderate control
- Dose
- 12mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Type 2 diabetes optimal control
- Dose
- 36mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Weight loss initiation (obesity without diabetes)
- Dose
- 6mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Weight loss progression (obesity without diabetes)
- Dose
- 12mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Weight loss optimization (obesity without diabetes)
- Dose
- 36mg daily
- Frequency
- Once daily, any time
- Route
- Oral tablet
Weight loss with type 2 diabetes
- Dose
- 6-36mg daily (titrate based on response)
- Frequency
- Once daily, any time
- Route
- Oral tablet
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is orforglipron approved?
Not yet. An FDA NDA was submitted in 2025 based on phase 3 data; approval decisions were pending at review date.
How does orforglipron differ from semaglutide?
It is a small-molecule (non-peptide) oral GLP-1 receptor agonist, so it is taken as a daily pill without injections or food restrictions.
What are the main side effects?
Gastrointestinal events (nausea, vomiting, diarrhea) are most common; some ALT elevations were seen in trials and are being monitored.
Research Citations
1
ATTAIN-1 Phase 3 Trial (Obesity) - 2025
(2025)
2
ATTAIN-2 Phase 3 Trial (Obesity + T2DM) - 2025
(2025)
3
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes) - 2025
(2025)
Related Resources
Quick Facts
Mechanism
Small-molecule GLP-1 receptor agonist with biased signaling - preferentially activates G protein/cAMP pathways (enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite) while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life supporting once-daily dosing.
Safety Information
Start with lowest effective dose and escalate gradually every 4 weeks to minimize GI side effects. Likely contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - pending final FDA labeling. Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to back) - discontinue if suspected. Diarrhea is most common side effect (more prevalent than with injectable GLP-1s) - stay well hydrated. Requires prescription and medical supervision - investigational until late 2025/2026 regulatory approval. Store at room temperature (15-30°C) - no refrigeration required unlike peptide GLP-1 agonists. May require adjustment of other diabetes medications (especially insulin or sulfonylureas) to prevent hypoglycemia. Not safe for use during pregnancy or breastfeeding - adequate contraception recommended during therapy. Gallbladder disease risk increased with rapid weight loss - monitor for symptoms. Discontinuation rates 5-10% due to adverse events, primarily GI-related during dose escalation.
Citations
31.ATTAIN-1 Phase 3 Trial (Obesity) - 2025
(2025)
2.ATTAIN-2 Phase 3 Trial (Obesity + T2DM) - 2025
(2025)
3.ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes) - 2025
(2025)